# Axis-Shield PoC AS 27 February 2014 510(k) Summary Afinion™M Lipid Panel and Afinion™M Lipid Panel Control

K132031

# 510(k) SAFETY AND EFFECTIVENESS SUMMARY

This summary of $5 1 0 ( \mathbf k )$ safety and efficacy information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: k132031

Submission type: 510 (k)

# Submitter/Owner:

Axis-Shield PoC AS Visiting address: Kjelsaasveien 161. N-0884 Oslo, Norway Postal address: P.O. Box 6863 Rodelokka, N-0504 Oslo, Norway

# Contact person:

Ms. Kari Skinnemoen, Regulatory Affairs Manager E-mail: kaskin@axis-shield.com

# Preparation date:

21 June 2013

# Device Name: Afinion™M Lipid Panel and Afinion™M Lipid Panel Control

<table><tr><td rowspan=1 colspan=1>Product code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>CHH - Total Cholesterol*</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.1175</td><td rowspan=1 colspan=1>75-Chemistry</td></tr><tr><td rowspan=1 colspan=1>LBR - HDL Cholesterol*</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.1475</td><td rowspan=1 colspan=1>75-Chemistry</td></tr><tr><td rowspan=1 colspan=1>JGY - Triglycerides*</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21CFR 862.1705</td><td rowspan=1 colspan=1>75-Chemistry</td></tr><tr><td rowspan=1 colspan=1>JJX - Quality Control material*</td><td rowspan=1 colspan=1>Class I</td><td rowspan=1 colspan=1>21 CFR 862.1660</td><td rowspan=1 colspan=1>75-Chemistry</td></tr></table>

\*Meets limitations of the exemption as per 21 CFR 862.9(c)(4).

Predicate Devices: The prdicate devices r Anion™ Lipid Panel are the following legallymarketed dvices:

Total Cholesterol   
Roche Diagnostics Corp.: COBAS INTEGRA CHOLESTEROL GEN.2; Submission   
K031824   
Triglycerides   
Roche Diagnostics Corp.: ROCHE COBAS InTEGRA REAGENT CASSETTES &   
ANCILLARY REAGENTS); Submission K972250   
HDL Cholesterol   
Siemens ADVIA 2400 Direct HDL Cholesterol; Submission K982341 (Original applicant:   
Randox laboratories, Ltd.)

Axis-Shield PoC AS 27 February 2014 510(k) Summary Afinion™M Lipid Panel and AfinionT™M Lipid Panel Control

he predicate device for Afinion™M Lipid Panel Control is the following legally marketed device:

Clinica Corp.: CLINIQA Liquid QC Lipid Controls Levels 1 and 2; Submission K061182

# Intended use/Indications for use

The Afinion™M Lipid Panel is an in vitro diagnostic test for quantitative determination of total cholesterol (Chol), high-density lipoprotein (HDL) cholesterol and triglycerides (Trig) in serum. Values for low-density lipoprotein (LDL) cholesterol, non-HDL cholesterol and Chol/HDL ratio are calculated by the Afinion™M AS100 Analyzer. Chol, HDL cholesterol, Trig, and calculated LDL cholesterol, non-HDL cholesterol and Chol/HDL ratio) are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders.

Afinion™M Lipid Panel Control has been designed for use with the Afinion™M AS100 Analyzer and Afinion™ Lipid Panel. Afinion™ Lipid Panel Control is intended for use as assayed control material for total cholesterol (Chol), high-density lipoprotein (HDL) cholesterol and triglycerides (Trig). The controls should be used to confirm that the Afinion™M AS100 Analyzer System is working properly and provides reliable results.

For usein clinical laboratories and point of care laboratory settings.

For prescription use only.

# Principle of the assay

Afinion™M Lipid Panel is a fully automated assay for quantitative determination of Chol, HDL and Trig in serum. LDL, non- HDL and Chol/HDL are calculated by the Afinion™M AS100 Analyzer.

The Afinion™M Lipid Panel Test Cartridge contains all reagents necessary for determination of Chol, HDL and Trig in serum. The sampling device integrated in the test cartridge is filled with pl alh   is he pain  alyzr. Te inspects the sampling device, and the sample is then diluted.

Total Cholesterol (Chol)

Total Cholesterol is measured by an enzymatic colorimetric method. Esterified and free cholesterol are enzymatically converted into cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide is used by hydrogen peroxidase to couple a phenol and 4-aminoantipyrin to a red quinoneimine dye. The color intensity is directly proportional to the concentration of free and esterified cholesterol in the sample.

# Triglycerides (Trig)

Triglycerides are measured by an enzymatic colorimetric method Triglycerides are enzymatically converted into glycerol by lipoprotein lipase. Glycerol is then further catalyzed in 2 steps to dihydroxy-acetone-phosphate and hydrogen peroxide. The hydrogen peroxide then reacts with 4 aminophenazone and 4-chlorophenol under the action of peroxidase to form a red dyestuff. The

# Axis-Shield PoC AS 27 February 2014 510(k) Summary Afinion™ Lipid Panel and Afinion™ Lipid Panel Control

color intensity is directly proportional to the concentration of triglycerides.

# HDL cholesterol

In a first reaction, anti-human apolipoprotein B (apoB) antibody (R1) binds to apoB present on all lipoproteins but HDL (i.e. non-HDL). The antibody protects non-HDL from being degraded by pegylated cholesterol metabolizing enzymes in the second reaction (R2). In the R2 reaction free and esterified cholesterol of HDL are converted into cholest-4-en-3-one and hydrogen peroxide. The hydrogen peroxide is used by peroxidase to couple 4-aminoantipyrin to F-DAOS and forms a blue color complex. The color intensity is directly proportional to the concentration of free and esterified HDL cholesterol.

# LDL cholesterol

NCEP recommends calculating LDL by use of the Friedwald formula2: LDL $\mathrm { ( m g / d L ) } = \mathrm { C h o l } - \mathrm { H D L } - \mathrm { T r i g } / 5$

This equation is not valid for non-fasting specimen, or in patients with type II h o   i  healyz he e above $4 0 0 \mathrm { m g / d L }$ as theFriedwald formula is less accurate at these triglyceride concentrations.

non-HDL cholesterol

The sum of VLDL (very low density lipoprotein) $+ \ \mathbf { L D L }$ is called non-HDL cholesterol. It is   
calculated routinely as total cholesterol minus HDL:   
non-HDL $=$ Chol - HDL

Chol/HDL ratio Chol/HDL $=$ Total Cholesterol/ HDL Cholesterol

# Traceability of Afinion™ Lipid Panel

Chol and HDL are traceable to the National Reference System for Cholesterol (NRS/CHOL). Trig is traceable to a Centers for Disease Control and Prevention (CDC) reference method.

Afinion™M Lipid Panel is CRMLN certified for Total Cholesterol and HDL Cholesterol.

Afinion™M Lipid Panel Kit contents (per 15 tests unit)

• 15 Test Cartridges packaged separately in foil pouches D 1 Package Insert

Materials required but not provided with the kit

$\bullet$ Afinion™ AS100 Analyzer $\bullet$ AfinionTM Lipid Panel Control $\bullet$ Standard blood collection equipment

# Axis-Shield PoC AS 27 February 2014 510(k) Summary AfinionTM Lipid Panel and Afinion™M Lipid Panel Control

# Target value assignment and traceability of Afinion™M Lipid Panel Control

The Afinion™M Lipid Panel is used for target value assignment of the Afinion™M Lipid Panel Control C I and C II. The target values and the corresponding acceptable ranges printed in the labeling are derived from replicate analyses (n=18)and are specific for each lot of product. Testing is performed on one operating day using 3 or 6 analyzers. The tests are performed by the manufacturer using Afinion™ Lipid Panel test cartridges and a representative sampling of the control lot.

Chol and HDL are traceable to the National Reference System for Cholesterol (NRS/CHOL). Trig is traceable to a Centers for Disease Control and Prevention (CDC) reference method.

Estimated target values for AfinionTM Lipid Panel Control   

<table><tr><td rowspan="2">Analyte</td><td colspan="2">Target value range (mg/dL) AfinionTM Lipid Panel Control</td></tr><tr><td>Control CI</td><td>Control CII</td></tr><tr><td>Total cholesterol</td><td>165-210</td><td>230-280</td></tr><tr><td>HDL cholesterol</td><td>34-46</td><td>52-70</td></tr><tr><td>Triglycerides</td><td>130-170</td><td>250-305</td></tr></table>

# Afinion™ Lipid Panel Control Stability

Real time stability studies were conducted to establish unopened and opened vial stabliy.   
Ao Lipid nel nol  nd  e easue ith e  pi n assy.   
All results were compared to the initial baseline results.

The AfinionTM Lipid Panel Controls were continuously stored at 2-8 °C (36-46 °F). Testing was performed monthly for 12 months. The study is on-going.

Afinion™M Lipid Panel Control CI and CII were subjected to an opened vial (in-use) stressing study. The vials were store a ${ 2 } { - } 8 ~ ^ { \circ } \mathrm { C }$ $( 3 6 { - } 4 6 ~ ^ { \circ } \mathrm { F } )$ te p    nts.T was performed after 7, 14 and 30 days, and thereafter weekly until 8 weeks. In between these testing points the vials were opened and samples withdrawn twice a week.

The acceptance criteria for Total Cholesterol, HDL Cholesterol and Triglycerides were: Recovery to baseline within $10 0 \pm 1 0 \%$ .

T   r :

12 months when stored refrigerated $( 2 \cdot 8 \ ^ { \circ } \mathrm { C }$ $3 6 { \cdot } 4 6 ^ { \circ } \mathsf { F } _ { \rho }$   
8 weeks when stored refrigerated $( 2 { - } 8 ^ { \circ } \mathbf { C } , 3 6 { - } 4 6 ^ { \circ } \mathbf { F } )$

AfinionTM Lipid Panel - Comparison of technological characteristics with predicate devices   

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Roche DiagnosticsCorp.Cholesterol</td><td rowspan=1 colspan=1>AfinionTM Lipid PanelAnalyte: Total Cholesterol (Chol)</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Enzymatic in vitro testfor the directquantitativedetermination ofcholesterol in humanserum and plasma onRoche automaticclinical chemistryanalyzers</td><td rowspan=1 colspan=1>The AfinionTM Lipid Panel is an in vitrodiagnostic test for quantitative determination oftotal cholesterol (Chol), high-density lipoprotein(HDL) cholesterol and triglycerides (Trig) inserum. Values for low-density lipoprotein (LDL)cholesterol, non-HDL cholesterol and Chol/HDLratio are calculated by the AfinionTM AS100Analyzer. Chol, HDL cholesterol, Trig, andcalculated LDL cholesterol, non-HDLcholesterol and Chol/HDL ratio) are used in thediagnosis and treatment of disorders involvingexcess cholesterol in the blood and lipid andlipoprotein metabolism disorders.For use in clinical laboratories and point of carelaboratory settings.</td></tr><tr><td rowspan=1 colspan=1>Test principle</td><td rowspan=1 colspan=1>Enzymaticcolorimetric test</td><td rowspan=1 colspan=1>Enzymatic colorimetric test.</td></tr><tr><td rowspan=1 colspan=1>Specimen type</td><td rowspan=1 colspan=1>SerumPlasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reporting range</td><td rowspan=1 colspan=1>3.86-800 mg/dL</td><td rowspan=1 colspan=1>100-500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Calibratedperiodically usingcalibrators supplied byvendor.</td><td rowspan=1 colspan=1>No calibration necessary by the user.Lot specific calibration via barcode on thecartridge. Calibration parameters are read by theanalyzer from the barcode before each run.</td></tr><tr><td rowspan=1 colspan=1>Sample volume</td><td rowspan=1 colspan=1>Sample isautomatically drawnfrom sample tube witha sample volume of atleast 0.5 mL.</td><td rowspan=1 colspan=1>15 μL</td></tr><tr><td rowspan=1 colspan=1>Test time</td><td rowspan=1 colspan=1>10 minutesBatch testing</td><td rowspan=1 colspan=1>8 minutesSingle tests</td></tr><tr><td rowspan=1 colspan=1>Testingenvironment</td><td rowspan=1 colspan=1>For use by health careprofessionals.Laboratory testing onautomated clinicalchemistry analyzers(Hitachi)</td><td rowspan=1 colspan=1>For use by health care professionals,Point of care testing using automated analyzer(AfinionTM AS100 Analyzer)</td></tr><tr><td rowspan=1 colspan=1>Assay reagents</td><td rowspan=1 colspan=1>Bottle of Reagent 1.</td><td rowspan=1 colspan=1>Ready to use test cartridges</td></tr><tr><td rowspan=1 colspan=1>Control material</td><td rowspan=1 colspan=1>8 controls available.</td><td rowspan=1 colspan=1>Afinion Lipid Panel Control:</td></tr></table>

Axis-Shield PoC AS 27 February 2014 510(k) Summary Afinion™M Lipid Panel and Afinion™M Lipid Panel Control   

<table><tr><td rowspan=1 colspan=1>available fromsupplier ofassay</td><td rowspan=1 colspan=1>Freeze-dried.</td><td rowspan=1 colspan=1>2 control levels. Ready to use.</td></tr><tr><td rowspan=1 colspan=1>Reagents andcontrols storageconditions</td><td rowspan=1 colspan=1>Refrigerated storage,2-8 °</td><td rowspan=1 colspan=1>Refrigerated storage, 2-8 </td></tr></table>

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Roche DiagnosticsCorp.Triglycerides</td><td rowspan=1 colspan=1>AfinionT Lipid PanelAnalyte: Triglycerides (Trig)</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Enzymatic in vitrotest for the directquantitativedetermination oftriglyceride inhuman serum andplasma on Rocheautomatic clinicalchemistry analyzers.</td><td rowspan=1 colspan=1>The AfinionTM Lipid Panel is an in vitro diagnostictest for quantitative determination of totalcholesterol (Chol), high-density lipoprotein (HDL)cholesterol and triglycerides (Trig) in serum. Valuesfor low-density lipoprotein (LDL) cholesterol, non-HDL cholesterol and Chol/HDL ratio are calculatedby the AfinionTM AS100 Analyzer. Chol, HDLcholesterol, Trig, and calculated LDL cholesterol,non-HDL cholesterol and Chol/HDL ratio) are usedin the diagnosis and treatment of disorders involvingexcess cholesterol in the blood and lipid andlipoprotein metabolism disorders.For use in clinical laboratories and point of carelaboratory settings.</td></tr><tr><td rowspan=1 colspan=1>Test principle</td><td rowspan=1 colspan=1>Enzymaticcolorimetric test</td><td rowspan=1 colspan=1>Enzymatic colorimetric test.</td></tr><tr><td rowspan=1 colspan=1>Specimen type</td><td rowspan=1 colspan=1>SerumPlasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reportingrange</td><td rowspan=1 colspan=1>8.85-885 mg/dL</td><td rowspan=1 colspan=1>45-650 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Calibratedperiodically usingcalibrators suppliedby vendor.</td><td rowspan=1 colspan=1>No calibration necessary by the user.Lot specific calibration via barcode on the testcartridge. Calibration parameters are read by theanalyzer from the barcode before each run.</td></tr><tr><td rowspan=1 colspan=1>Samplevolume</td><td rowspan=1 colspan=1>Sample isautomatically drawnfrom sample tubewith a samplevolume of at least0.5 mL.</td><td rowspan=1 colspan=1>15μL</td></tr><tr><td rowspan=1 colspan=1>Test time</td><td rowspan=1 colspan=1>5 minutesBatch testing</td><td rowspan=1 colspan=1>8 minutesSingle tests</td></tr></table>

Axis-Shield PoC AS 27 February 2014 510(k) Summary Afinion™M Lipid Panel and Afinion™M Lipid Panel Control   

<table><tr><td rowspan=1 colspan=1>Testingenvironment</td><td rowspan=1 colspan=1>For use by healthcare professionals.Laboratory testingon automatedclinical chemistryanalyzers (Hitachi)</td><td rowspan=1 colspan=1>For use by health care professionalsPoint of care testing using automated analyzer(AfinionTM AS100 Analyzer)</td></tr><tr><td rowspan=1 colspan=1>Assay reagents</td><td rowspan=1 colspan=1>Bottle of Reagent 1.</td><td rowspan=1 colspan=1>Ready to use test cartridges</td></tr><tr><td rowspan=1 colspan=1>Controlmaterialavailable fromsupplier of test</td><td rowspan=1 colspan=1>8 controls available.Freeze-dried.</td><td rowspan=1 colspan=1>Afinion Lipid Panel Control:2 control levels. Ready to use.</td></tr><tr><td rowspan=1 colspan=1>Reagents andcontrolsstorageconditions</td><td rowspan=1 colspan=1>Refrigerated storage,2-8 °</td><td rowspan=1 colspan=1>Refrigerated storage, 2-8 C</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Siemens ADVIA2400HDL-Cholesterol</td><td rowspan=1 colspan=1>AfinionTM Lipid PanelAnalyte: HDL Cholesterol</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>For in vitrodiagnostic use in thequantitativedetermination ofHDL cholesterol inhuman serum andplasma on theADVIA Chemistrysystems. Suchmeasurements areused in the riskassessment ofcoronary arterydisease</td><td rowspan=1 colspan=1>The AfinionTM Lipid Panel is an in vitro diagnostictest for quantitative determination of totalcholesterol (Chol), high-density lipoprotein (HDL)cholesterol and triglycerides (Trig) in serum. Valuesfor low-density lipoprotein (LDL) cholesterol, non-HDL cholesterol and Chol/HDL ratio are calculatedby the AfinionTM AS100 Analyzer. Chol, HDLcholesterol, Trig, and calculated LDL cholesterol,non-HDL cholesterol and Chol/HDL ratio) are usedin the diagnosis and treatment of disorders involvingexcess cholesterol in the blood and lipid andlipoprotein metabolism disorders.For use in clinical laboratories and point of carelaboratory settings.</td></tr><tr><td rowspan=1 colspan=1>Test principle</td><td rowspan=1 colspan=1>Enzymaticcolorimetric test.Direct determinationof HDL-cholesterol.Cholesterol fromnon-HDL particles iseliminated in thefirst reaction step.</td><td rowspan=1 colspan=1>Enzymatic colorimetric test.Direct determination of HDL by initial antibodyblocking of apolipoprotein B (apo-B) , which ispresent on all lipoproteins except HDL cholesterol.</td></tr></table>

Axis-Shield PoC AS 27 February 2014 510(k) Summary Afinion™M Lipid Panel and Afinion™M Lipid Panel Control   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>In second stepcholesterol in HDLparticles is releasedby detergent andmeasured by aTrinder reaction.</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Specimen type</td><td rowspan=1 colspan=1>SerumPlasma</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Reportingrange</td><td rowspan=1 colspan=1>5-115 mg/dL</td><td rowspan=1 colspan=1>15-100 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Calibratedperiodically usingcalibrators suppliedby vendor.</td><td rowspan=1 colspan=1>No calibration necessary by the user.Lot specific calibration via barcode on the cartridge.Calibration parameters are read by the analyzerfrom the barcode before each run.</td></tr><tr><td rowspan=1 colspan=1>Samplevolume</td><td rowspan=1 colspan=1>Sample isautomatically drawnfrom sample tubewith a samplevolume of at least0.5 mL.</td><td rowspan=1 colspan=1>15 μL</td></tr><tr><td rowspan=1 colspan=1>Test time</td><td rowspan=1 colspan=1>10 minutesBatch testing</td><td rowspan=1 colspan=1>8 minutesSingle tests</td></tr><tr><td rowspan=1 colspan=1>Testingenvironment</td><td rowspan=1 colspan=1>For use by healthcare professionals.Laboratory testingon automatedclinical chemistryanalyzers (ADVIA))</td><td rowspan=1 colspan=1>For use by health care professionalsPoint of care testing using automated analyzer(Afinion™M AS100 Analyzer)</td></tr><tr><td rowspan=1 colspan=1>Assay reagents</td><td rowspan=1 colspan=1>Bottles of Reagent 1and Reagent 2</td><td rowspan=1 colspan=1>Ready to use test cartridges</td></tr><tr><td rowspan=1 colspan=1>Storageconditions</td><td rowspan=1 colspan=1>Refrigerated storage,2-8 °C</td><td rowspan=1 colspan=1>Refrigerated storage, 2-8 °</td></tr><tr><td rowspan=1 colspan=1>Controlmaterial</td><td rowspan=1 colspan=1>2 control levelsrecommended.Available from Bio-Rad Laboratories.</td><td rowspan=1 colspan=1>Afinion Lipid Panel Control:2 control levels. Ready to use.</td></tr></table>

Axis-Shield PoC AS 27 February 2014 510(k) Summary Afinion™M Lipid Panel and Afinion™M Lipid Panel Control   
AfinionTM Lipid Panel Control - Comparison of technological characteristics with predicate device   

<table><tr><td rowspan=1 colspan=1>yYIe</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Cliniqa Liquid QC LipidControl</td><td rowspan=1 colspan=1>AfinionTM Lipid Panel Control</td></tr><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>CLINIQA Liquid QC LipidControl is intended for use as anassayed quality control material forApolipoprotein A-1,Apolipoprotein B, Cholesterol(Total), High Density Lipoprotein,Low Density Lipoprotein andTriglycerides.</td><td rowspan=1 colspan=1>AfinionTM Lipid Panel Control isintended for use as assayed controlmaterial for total cholesterol(Chol), high-density lipoprotein(HDL) cholesterol andtriglycerides (Trig).</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum</td><td rowspan=1 colspan=1>Human serum*</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Total CholesterolHDL CholesterolTriglycerides</td><td rowspan=1 colspan=1>Total CholesterolHDL CholesterolTriglycerides</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Liquid — ready to use</td><td rowspan=1 colspan=1>Liquid — ready to use</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Storageconditions</td><td rowspan=1 colspan=1>2-8°C</td><td rowspan=1 colspan=1>2-8°C</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Analytes</td><td rowspan=1 colspan=1>Target values also available forApoLipoprotein A1 andApolipoprotein B and LDLCholesterol.</td><td rowspan=1 colspan=1>No target values forApoLipoprotein Al andApolipoprotein B as they are notmeasured by AfinionTM LipidPanel.LDL cholesterol is calculated byAfinionTM AS100 Analyzer, and notarget value for LDL is assigned.</td></tr><tr><td rowspan=1 colspan=1>Kit size</td><td rowspan=1 colspan=1>3 x 2 x 3 mLorL1: 6 x 3 mL and L2: 6 x 3 mL</td><td rowspan=1 colspan=1>2 x l x 1.0 mL</td></tr><tr><td rowspan=1 colspan=1>Target valueassignment</td><td rowspan=1 colspan=1>Target values are methoddependent, and assigned values areavailable for a large number ofmethods/systems.</td><td rowspan=1 colspan=1>Target values are assigned forAfinionTM Lipid Panel.</td></tr></table>

\* Each serum/plasma donor unit used in the manufacture of the control products has been tested by FDA accepted methods and found non-reactive for the presence of HBsAg and antibody to HIV1/2, HCV and HIV-1 Ag.

# Axis-Shield PoC AS 27 February 2014 510(k) Summary Afinion™M Lipid Panel and Afinion™M Lipid Panel Control

# Linearity

ThL according to CLSI Guideline EP6-A. The study was performed measuring dilution series with serum samples. One low and one high sample were intermixed to produce 1 1 concentration levels for each analyte. Each level was measured in 4-6 replicates. The linear regression lines for comparison of measured concentration (y) and theoretical concentration $\mathbf { \rho } ( \mathbf { x } )$ are:

Total cholesterol: $\mathrm { y } { = } 1 . 0 0 0 \mathrm { x } - 4 . 5 \mathrm { m g } / \mathrm { d L }$ $\mathrm { r } ^ { 2 } { = } 0 . 9 9 5$ Triglycerides: $\mathbf { y } { = } 1 . 0 0 9 \mathbf { x } - 2 . 9 \mathbf { m } \mathbf { g } / \mathrm { d L }$ $\mathrm { r } ^ { 2 } { = } 0 . 9 9 9$ HDL Cholesterol: EY $\mathrm { y } { = } 0 . 9 9 1 \mathrm { x } - 2 . 4 \mathrm { m g } / \mathrm { d L }$ $\mathrm { r } ^ { 2 } { = } 0 . 9 9 4$

Linearity for Total Cholesterol, Triglycerides and HDL Cholesterol using serum samples has been demonstrated over the following ranges:

Total cholesterol: 77-511 mg/dL (Reportable range $\mathsf { I } 0 0 { - } 5 0 0 \ \mathrm { m g / d L } )$ Triglycerides: 36-691 mg/dL (Reportable range $4 5 { \cdot } 6 5 0 \ \mathrm { m g / d L } )$ HDL Cholesterol: 14-111 mg/dL (Reportable range $1 5 { - } 1 0 0 \ \mathrm { m g / d L } )$ EMPY

# Limits of Quantitation

Limits of quantitation have been established according to CLSI Guideline EP-17A, which determines Limits of quantitation (LoQ) based on determination of limits of blank (LoB) and Limits of Detection (LoD). 5 samples with concentration near $0 \mathrm { m g / d L }$ (LoB samples) were measured in totally 60 replicates using 3 analyzers and 2 Afinion™ Lipid Panel test cartridge lots. 5 low concentration samples (LoD samples) were tested according to the same test scheme. LoQ was estimated based on the established LoD.

The following limits of quantitation have been established or Afinion™ Lipid Panel in serum:

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Total Cholesterol</td><td rowspan=1 colspan=1>HDL Cholesterol</td><td rowspan=1 colspan=1>Triglycerides</td></tr><tr><td rowspan=1 colspan=1>LoQ (mg/dL)</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>5.9</td></tr></table>

# Analytical specificity

Design verification studies have been performed to investigate whether any endogenous and exogenous substances interfere with the Afinion™ Lipid Panel assay. The studies have been performed in accordance with CLSI guideline EP7-A2.

Interference effect from 28 substances has been evaluated, among commonly used antibiotics, statins, analgesic agents, immune-suppressants and anticoagulants. The substances tested are those previously assesse within the predicate devices, substances found to interfere with lipid tests based on a literature search. In addition the most common drugs used for lipid-lowering therapy and diabetic management have been tested.

# Axis-Shield PoC AS 27 February 2014 510(k) Summary Afinion™M Lipid Panel and AfinionTM Lipid Panel Control

The substances listed below were tested for interference with the measurements of Chol, HDL and Trig. Samples covering two medical decision concentrations of each lipid analyte were measured. No significant interference $( < 1 0 \% )$ was observed up to the following concentrations:

• Acetaminophen $2 0 0 ~ \mathrm { { m g / L } }$ • Acetylsalicylic acid $1 0 0 0 \mathrm { m g / L }$ $\bullet$ Acetylcysteine $1 5 9 0 \mathrm { m g / L }$ $\bullet$ Ampicillin $1 0 0 0 \mathrm { m g / L }$ $\bullet$ Ascorbic acid $6 ~ \mathrm { m g / d L }$ $\bullet$ Atorvastatin $6 0 0 ~ \mu \varrho / \mathrm { L }$ $\bullet$ Bilirubin (conjugated and unconjugated) $2 0 \mathrm { m g / d L }$ • Calcium dobesilate $0 . 7 \mathrm { m g / d L }$ • Cefoxitin $2 5 0 0 \mathrm { m g / L }$ EY • CyclosporineA $\sin \theta / \mathrm { L }$ • CyclosporineC $\bar { 5 } \mathrm { m g / L }$ $\bullet$ Fluvastatin $2 . 9 7 \mathrm { m g / L }$ • Hemoglobin (hemolysis) $0 . 5 \ : \mathrm { g / d L }$

Heparin 3000 U/L $\bullet$ Ibuprofen $5 0 0 \mathrm { m g / L }$ $\bullet$ Intralipid $1 0 0 0 0 \mathrm { m g / L }$ • Levodopa $1 5 \mathrm { m g / L }$ • Lovastatin $2 1 6 ~ \mu \mu / \mathrm { L }$ • Metformin $4 0 \mathrm { m g / L }$ • Methyldopa $1 . 4 ~ \mathrm { m g / d L }$ $\bullet$ Metronidazole $2 0 0 ~ \mathrm { { m g / L } }$ $\bullet$ Pravastatin $7 . 3 2 \mathrm { m g / L }$ $\bullet$ Rifampicin $6 4 . 3 ~ \mathrm { m g / L }$ • Simvastatin $8 0 . 4 \mu \mathrm { g / L }$ • Theophylline $1 0 0 ~ \mathrm { { m g / L } }$ D Tetracycline $5 0 ~ \mathrm { m g / L }$ EY

# Limitations:

Calcium dobesilate interferes with Afinion™M Lipid Panel at therapeutic levels and results ir falsely low results for Chol, HDL and Trig.   
Methyldopa concentrations above $1 . 4 \ : \mathrm { m g / d L }$ inte with ino Lipid ne and may give falsely low Trig results. This is above toxic levels of Methyldopa and there is no interference at therapeutic levels.   
Acetylcysteine concentrations above $1 5 9 0 \mathrm { m g / L }$ may give falsely low Trig results. This is above the drug concentration at therapeutic level.   
Levodopa concentrations above $1 5 \mathrm { m g / L }$ may give falsely low HDL and Trig results. This is above the drug concentration at therapeutic level.

# Accuracy

A method comparison was performed between Afinion™M Lipid Panel and automated laboratory methods (CM) for Chol, Trig and HDL. The study was performed at four point-of-care sites. The study was performed according to CLSI guideline EP09-A2-IR, except that single replicates per sample was used for the Afinion™ Lipid Panel measurements and not duplicates as stated in the guideline. Regression analysis results for each analyte in serum are summarized in table 1. Bias at medical decision levels and elevated concentration levels are summarized in table 2. Bland-Altman plots are presented in figures 1-3.

# Axis-Shield PoC AS 27 February 2014 E $5 1 0 ( \mathbf { k } )$ Summary Afinion™M Lipid Panel and Afinion™ Lipid Panel Control

Table 1 Method comparison results for serum.   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Number ofsamples</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Correlationcoefficient (r)</td><td rowspan=1 colspan=1>Range</td></tr><tr><td rowspan=1 colspan=1>Chol</td><td rowspan=1 colspan=1>348</td><td rowspan=1 colspan=1>-4.5 mg/dL</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>105.5 - 466.0 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Trig</td><td rowspan=1 colspan=1>246</td><td rowspan=1 colspan=1>-11.4 mg/dL</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>1.00</td><td rowspan=1 colspan=1>55.5-616.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>HDL</td><td rowspan=1 colspan=1>251</td><td rowspan=1 colspan=1>-2.1 mg/dL</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>23.2-92.7 mg/dL</td></tr></table>

Table 2 Calculated bias (in ${ \mathrm { ~ } } _ { \mathrm { { m g / d L } } }$ and $\%$ ) at different concentration levels for serum   
Bland-Altman of Total Cholesterol Serum   

<table><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Concentrationlevel (mg/dL)</td><td rowspan=1 colspan=1>Bias(mg/dL)</td><td rowspan=1 colspan=1>Bias (%)</td></tr><tr><td rowspan=3 colspan=1>Trig</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>-5.0</td><td rowspan=1 colspan=1>-3.3</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>-2.8</td><td rowspan=1 colspan=1>-1.4</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>2.0</td></tr><tr><td rowspan=3 colspan=1>Chol</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>9.7</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=3 colspan=1>HDL</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>-0.6</td><td rowspan=1 colspan=1>-1.6</td></tr><tr><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.1</td></tr><tr><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.0</td></tr></table>

![](images/75490ad2411d423d109e636fed46691940405084cdf19b2feeffd77db68cc1b5.jpg)  
Fiure 1 Bland-Altman plot  total cholestero, serum Difference ngL

# Bland-Altman of HDL Cholesterol Serum

![](images/228d7fdab72a1f22e9714513b1a0ba978db91dd9c8009ca7b2f25eae9d1d5b6f.jpg)  
Figure 2 Bland-Altman plot of HDL cholesterol, serum. Difference in mg/dL.

# Bland-Altman of Triglycerides Serum

![](images/8b98c937a64fc7caf6d1134db7a4dad774c71c75bc6bb4107398f817e61842e1.jpg)  
Figure 3 Bland-Altman plot of Triglycerides, serum. Difference in mg/dL.

# Axis-Shield PoC AS 510(k) Summary Afinion™M Lipid Panel and Afinion™M Lipid Panel Control

# Precision

Repeatability and within-device (total) precision were determined according to the CLSI Guideline EP5-A2. The precision study was performed at three point-of-care sites using one lot of Afinion™ Lipid Panel test cartridges and 2-3 analyzers per site.

Two controls and one serum sample were tested with 2 replicates per run and 2 runs per day for 2( days with a total of 80 replicates at each site. The results are summarized in tables 3-5.

Table 3: Cholesterol. Repeatability and Within-device precision (total), N=number of replicates, ${ \bf S } { \bf D } { = } { \bf S }$ tandard deviation, $C \mathrm { V } { = } \mathrm { C o e }$ fficient of Variation.   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>Site</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within-device</td></tr><tr><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=3 colspan=1>Control sample</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>185.8</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>186.5</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>6.7</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>186.3</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=3 colspan=1>Control sample</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>249.2</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>252.4</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>249.3</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=3 colspan=1>Serum sample</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>400.0</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>401.4</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>401.4</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>2.8</td></tr></table>

Table 4: HDL. Repeatability and Within-device precision (total), N=number of replicates, $\mathbf { S } \mathbf { D } { = } \mathbf { S }$ tandard deviation, $\mathrm { C V = C o }$ efficient of Variation.   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>Site</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within-device</td></tr><tr><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=3 colspan=1>Control sample</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>39.8</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.2</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>40.6</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>4.9</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>40.1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=3 colspan=1>Control sample</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>57.1</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.8</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>59.4</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>57.9</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>3.6</td></tr><tr><td rowspan=3 colspan=1>Serum sample</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>70.8</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>72.8</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>72.0</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>2.6</td></tr></table>

Axis-Shield PoC AS 27 February 2014 510(k) Summary Afinion™M Lipid Panel and Afinion™M Lipid Panel Control   
Table 5: Triglycerides. Repeatability and Within-device precision (total), $\mathbf { N } { = }$ number of replicates $\mathbf { S D } \mathbf { = S }$ tandard deviation, $\mathbf { C V = C }$ oefficient of Variation.   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=2 colspan=1>Site</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Mean(mg/dL)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Within-device</td></tr><tr><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD(mg/dL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=3 colspan=1>Control sample</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>153.8</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>154.5</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>154.8</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=3 colspan=1>Control sample</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>276.2</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>279.1</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>10.4</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>276.0</td><td rowspan=1 colspan=1>12.2</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>13.4</td><td rowspan=1 colspan=1>4.9</td></tr><tr><td rowspan=3 colspan=1>Serum sample</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>343.5</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>344.1</td><td rowspan=1 colspan=1>10.6</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>13.5</td><td rowspan=1 colspan=1>3.9</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>343.3</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>12.3</td><td rowspan=1 colspan=1>3.6</td></tr></table>

# Conclusion

Comparison of information characterizing the Afinion Total Cholesterol, Triglyceride and HDL Cholesterol assays and the Afinion Lipid Panel controls for use on the Afinion AS 100 Analyzer including results of the method comparison, precision, sensitivity, specificity, bias, and linerity studies, as well as the value assignment and stability studies for the Lipid Panel controls showed the results to be substantially equivalent to the predicate devices.

March 21, 2014

AXIS-SHIELD POC AS   
KARI SKINNEMOEN   
P.O. BOX 6863   
RODELOKKA   
OSLO N-0504, NORWAY

Re: K132031 Trade/Device Name: AfinionTM Lipid Panel AfinionT Lipid Panel Control Regulation Number: 21 CFR 862.1175 Regulation Name: Cholesterol (total) test system Regulatory Class: I, Meets limitations of the exemption as per 21 CFR 862.9(c)(4). Product Code: CHH, LBR, JGY, JJY Dated: February 10, 2014 Received: February 12, 2014

Dear Ms. Skinnemoen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The gneral controls provisions o theAct includerequirements or annual registration, list devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note:CDRH does not evaluate information related to contract liability warranties.We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 1, Parts 800 to 88. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 8 pleasc contact the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address http://wwwv.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also. please notc the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part .9F  arhor e ner  ua CFR Part 803). please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address htp://www.fda.gov/MedicalDevices/RcsourcesforYou/Industry/default.htm.

Sincerely yours.

# Courtney H. Lias -S

Courtney H. Lias. Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

510(k) Number (if known) k132031

Device Name Afinion™ Lipid Panel and Afinion™ Lipid Panel Control

# indications for Use (Describe)

y Hchoo n iglyce Trii sVlu or owensiy LL oD involving excess cholesterol inhe blood and lipid and lipoprotein metabolism disorders.

al al properly and provides reliable results.

For use n clinical laboratories and pointof care laboratory settings.

For prescription use only.

# Ruth A. Chesler -S